DISCOUNT OPTIONSSCHEIN - MADRIGAL PHARMACEUTICALS | Market Closed - Börse Stuttgart 04:21:31 2024-05-28 EDT | ||
| 1.07 EUR | +0.94% |
|
| Current month | +9.18% | ||
| 1 month | +42.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about MADRIGAL PHARMACEUTICALS, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 1.07 | +0.94% |
| 24-05-27 | 1.06 | -7.02% |
| 24-05-24 | 1.14 | +0.88% |
| 24-05-23 | 1.13 | -5.83% |
| 24-05-22 | 1.2 | +13.21% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 04:21 am
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MADRIGAL PHARMACEUTICALS, INC. |
| Issuer | Morgan Stanley |
| WKN | MG0D7H |
| ISIN | DE000MG0D7H3 |
| Date issued | 2024-03-18 |
| Strike | 350 $ |
| Maturity | 2025-03-21 (297 Days) |
| Parity | 10 : 1 |
| Emission price | 1.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.84 € |
|---|---|
| Lowest since issue | 0.72 € |
Company Profile
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Companyâs clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
-
Consensus: Madrigal Pharmaceuticals, Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
223.3
USD
Average target price
363.9
USD
Spread / Average Target
+62.95%
- Stock Market
- Certificates
- Certificat
